ArticleAdvances in therapy2023

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.

Takashi Ogura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.